STAMFORD, Conn. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that

STAMFORD, Conn. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced

STAMFORD, Conn. , July 27, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that

Tablet strengths exhibiting appropriate plasma levels identified for potential use in general CKD-associated pruritus patients

- Statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose - - 35 percent reduction in mean joint pain score for all patients at eight weeks with 5.0 mg dose - - All tablet strengths well tolerated over eight-week treatment period - -

Phase 3 safety extension trial underway

- Trial will continue to test two doses of CR845 and aims to enroll up to 450 patients - - Both doses of CR845 well tolerated - - Trial completion expected in the fourth quarter of 2017 - STAMFORD, Conn. , June 21, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.

Dr. Joseph Stauffer to deliver opening remarks and discuss kappa opioid receptor agonists as a novel approach to acute and chronic pain management Dr. Stauffer serves as co-chair and on the event's Scientific Advisory Board STAMFORD, Conn. , May 17, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.

STAMFORD, Conn. , May 12, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that

- Reported statistically significant positive top-line results from Part A of Phase 2/3 trial for I.V. CR845 in chronic kidney disease (CKD)-associated pruritus -  - Completed public offering of common stock, raising net proceeds of $86.5 million -  - Conference call today at 4:30 p.m.